Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.
康涅狄格州斯坦福，2024年4月2日（GLOBE NEWSWIRE）——Cara Therapeutics, Inc.（納斯達克股票代碼：CARA）是一家處於開發階段的生物製藥公司，領導着改善瘙癢症患者生活的新治療模式。該公司今天宣佈，總裁兼首席執行官克里斯托弗·波斯納將出席第23屆會議第三方 年度尼德姆虛擬醫療保健會議將於美國東部時間2024年4月9日星期二上午8點40分舉行。
A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
該演講的網絡直播可在公司網站 “投資者” 部分的 “活動與演講” 下觀看 www.caratheapeutics。Cara網站上將提供存檔的網絡直播錄像，爲期約30天。
About Cara Therapeutics
關於卡拉療法
Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide. For more information, visit www.CaraTherapeutics.com and follow the company on X (Twitter), LinkedIn and Instagram.
Cara Therapeutics是一家處於開發階段的生物製藥公司，領導着一種新的治療模式，旨在改善瘙癢患者的生活。該公司正在開發difelikefalin的口服配方，這是一種選擇性、外周作用、非定期的kappa阿片類藥物受體激動劑，用於治療與痛經（NP）相關的慢性瘙癢，這是一種常見的、診斷不足、影響上背部的神經病變，沒有獲得美國食品藥品管理局批准的療法。該公司正在NP進行2/3期臨床項目，劑量發現部分的主要結果預計將在2024年第三季度公佈。Cara Therapeutics還開發了difelikefalin的靜脈注射配方，該配方已獲得美國、歐盟和其他多個國家的批准，用於治療接受血液透析的成人中度至重度慢性腎臟病相關的中度至重度瘙癢。靜脈注射配方已在全球範圍內獲得授權。欲了解更多信息，請訪問 www.caratheapeutics 然後繼續關注該公司 X (Twitter)， 領英 和 Instagram。
MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com
媒體聯繫人：
安妮·斯皮內塔
6 度
973-768-2170
aspinetta@6degreespr.com
INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com
投資者聯繫人：
艾里斯·弗朗西斯科尼博士
卡拉療法
203-406-3700
investor@caratherapeutics.com
Source: Cara Therapeutics, Inc.
來源：Cara Therapeutics, Inc.
譯文內容由第三人軟體翻譯。